J&J in talks with Indian govt to speed up delivery of its Covid-19 vaccine

The Economic Times newspaper reported earlier on Tuesday that the company would no longer undertake local trials for its vaccine

Johnson & Johnson's Vaccine, J&J, Coronavirus vaccine
Photo: Shutterstock
Reuters
1 min read Last Updated : Jun 29 2021 | 5:01 PM IST
Johnson & Johnson (J&J) said on Tuesday it was in talks with the Indian government to explore ways to speed up delivery of its single-shot Covid-19 vaccine in the country.

The Economic Times newspaper reported earlier on Tuesday that the company would no longer undertake local trials for its vaccine, after India's decision to scrap bridging clinical trials for vaccines approved by regulators in other nations.

J&J did not specify in its comment whether it has scrapped the trial.

The US-based company said in April it was seeking an approval to conduct a bridging clinical study of its Janssen Covid-19 vaccine candidate in India. read more

In late-May, however, the country scrapped local trials for "well-established" vaccines manufactured in other countries. read more

More than 41 million vaccine doses were administered across India in just the last one week, at a time when experts have said that widespread vaccination remains one of the best tools to avoid the kind of devastation the country saw during the pandemic's second wave.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

Next Story